Back to All

ESMO23: Diaceuticsโ€™ key takeaways

26 October, 2023

The European Society for Medical Oncology (ESMO) Congress 2023, held in Madrid from October 20th to 24th, brought together thousands of oncology professionals, researchers, and industry leaders who shared the latest breakthroughs and innovations in cancer care. Diaceutics were there to gain knowledge from the world-leading experts and provide insights and advice to our customers on the new findings.

Our precision medicine expert Tessa Sandberg attended the Congress and shared her daily highlights on our social media channels. In this blog post, we will recap some of the key insights from the four days of the conference, focusing on precision medicine topics such as biomarker testing, targeted therapies, and companion diagnostics.

Day 1: Promising results for radioligand therapy, pembrolizumab, and HER2 testing

The first day of the congress featured several presentations on novel therapies and biomarkers for various types of cancers. Some of the highlights were:

  • Promising results of enzalutamide + radioligand therapy in metastatic castration resistant prostate cancer (mCRPC): The ENZA-p trial showed a survival benefit for the combination versus enzalutamide alone. This is the first trial to combine enzalutamide with radioligand therapy in mCRPC, and the results suggest that this combination could become a new standard of care.
  • Benefit of adding pembrolizumab to trastuzumab and chemotherapy in HER2+ gastric/esophagogastric junction (Gastric/GEJ) in first line therapy: The KEYNOTE-811 trial showed an OS and PFS benefit, especially in PD-L1 positive cancers. These results led to the EMA approval this year in PD-L1 positive gastric/GEJ cancers.
  • HER2 testing in metastatic colorectal cancer (mCRC) may shift to earlier line: The results of MOUNTAINEER-03 trial are in progress, testing trastuzumab and tucatinib in 1L HER2+ and RAS WT mCRC. A poll at the conference showed that nearly all respondents (92%) believe HER2 testing should be performed at diagnosis of metastatic disease. However, ESMO guidelines do not (yet) recommend this. This suggests that we may see a shift towards earlier HER2 testing in mCRC, which could lead to more patients benefiting from targeted therapies. At Diaceutics, we believe that every patient should receive the right test and the right treatment to positively impact their disease outcome, and we strongly encourage the uptake of early testing for better treatment.


Day 2: Rare mutations in NSCLC get new targeted therapies

The second day of the congress focused on therapies targeting rare mutations in non-small cell lung cancer (NSCLC). At Diaceutics we understand the importance of comprehensive testing early on to find the right patient for the right drug. Some of the highlights were:

  • 1L amivantamab plus chemotherapy showed survival benefit in advanced NSCLC with an EGFR exon 20 insertion: The PAPILLON trial established a new standard of care for patients with this rare mutation. Amivantamab plus chemotherapy in NSCLC with an EGFR exon 20 insertion significantly improved survival compared to chemotherapy alone, and these results are likely to lead to adoption of this combination in clinical practice.
  • 1L selpercatinib showed survival benefit in RET fusion+ NSCLC: The LIBRETTO-431 trial showed a PFS benefit for selpercatinib as a first-line therapy of choice compared to chemotherapy and pembrolizumab. This is the first time that a targeted therapy has been shown to outperform immunotherapy in this setting, and it highlights the importance of precision medicine in the treatment of NSCLC. The evidence of this trial will hopefully lead to reimbursement in European countries where it was pending the results of this trial.
  • Significant benefit of adjuvant alectinib versus chemotherapy in ALK+ early-stage NSCLC: The interim analysis ALINA trial showed a DFS and safety benefit for alectinib compared to chemotherapy. While awaiting the OS data, these positive results of ALK inhibition may lead to practice changes for patients with ALK+ early-stage NSCLC.
  • Durable response of zenocutuzumab in advanced NSCLC with a NRG1 fusion: The eNRGy phase 2 trial showed promising durable efficacy for zenocutuzumab, a HER2 x HER3 bispecific antibody in NRG1+ advanced NSCLC. The authors argued that zenocutuzumab represents the first and best in class therapy for NRG1+ NSCLC.

Day 3: Breast cancer and immunotherapy get new developments

On the third day of the conference unique results were presented in bladder cancer. While these drugs do not require predictive testing, they impact current testing and treatment practices.

  • Enfortumab Vedotin in combination with pembrolizumab (EV+P) as new 1L therapy in advanced metastatic bladder cancer: The presentation of the final results of the KEYNOTE-A39 clinical trial gained a standing ovation as results showed EV+P outperforming chemotherapy for the first time in 1L bladder cancer. A second trial, the CheckMate 901, showed the benefit of nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone in unresectable or metastatic bladder cancer. Similar to KEYNOTE-A39, the CheckMate 901 trial outperformed the current standard of care in 1L bladder cancer. However, it did not outperform the KEYNOTE-A39 results. The KEYNOTE-A39 trial showed a PFS and OS benefit for EV+P over chemotherapy. This is the first time that an immunotherapy combination has been shown to outperform chemotherapy in first-line advanced metastatic bladder cancer, and it establishes EV+P as a new standard of care in this setting.
  • Encouraging anti-tumor activity and safety of RMC-6236, first in class, in NSCLC and PDAC with different genotypes in KRAS G12X: RMC-6236 is a highly innovative RAS-selective inhibitor with the potential to treat a wider range of RAS-mutated cancers, including KRAS G12D and G12V. The early-phase results presented at ESMO 2023 were encouraging, showing anti-tumor activity and a favorable safety profile.


Day 4: Novel approaches for melanoma, ovarian cancer, and glioblastoma

The fourth and final day of the congress presented novel approaches for melanoma, ovarian cancer, and glioblastoma. Some of the highlights were:

  • Center of Excellence for the successful adoption of a complex test in a German academic laboratory - a case study: Following the promising results of the PAOLA-1 clinical trial in 2019, Germany prepared for the adoption of Homologous Recombination Deficiency (HRD), a biomarker tested with a complex assay. The Marburg lab implemented a Myriad MyChoice test to give German patients access to the drug upon launch. At Diaceutics, we know that testing is key for drug adoption and setting up a center of excellence is a great short-term opportunity to adopt testing. This case study highlights the importance of collaboration between academia and industry in the successful adoption of precision medicine approaches.
  • Improvements in 1L and 2L treatment in EGFR-mutated metastatic NSCLC: The MARIPOSA and MARIPOSA-2 trials showed benefit over the standard of care for both 1L and 2L treatment of EGFR-mutated metastatic NSCLC. In MARIPOSA, amivantamab + lazertinib showed PFS benefit compared to osimertinib in 1L therapy. MARIPOSA-2 results showed that amivantamab plus chemotherapy with or without lazertinib vs chemotherapy is a new treatment option in 2L  post-osimertinib. With the increased number of treatment options in EGFR+ NSCLC, will there be a way to select which patients will benefit most from which treatment? For instance, using the biomarker MET for amivantamab targeting both EGFR and MET? These results suggest that we are making significant progress in improving outcomes for patients with this type of cancer.
  • The future of digital pathology in clinical practice: In this special session, a pathologist highlighted the challenges of integrating digital pathology into clinical practice while acknowledging the potential to integrate complex biomarkers and improve patient management. For instance, through 1) reducing human error, 2) discovering new types of features, and 3) integrating multi-modal data. Digital pathology is a rapidly developing field with the potential to transform cancer diagnosis and treatment, and the discussion at ESMO 2023 highlighted the importance of this technology.



ESMO 2023 featured a number of promising new developments in cancer treatment and diagnostics, including new targeted therapies for rare mutations in NSCLC and new immunotherapies for bladder cancer. The conference also highlighted the growing importance of precision medicine and the need for more comprehensive testing at the time of diagnosis.

Diaceutics would like to extend our congratulations and thanks to every individual who helped to make these significant treatment breakthroughs possible. We were extremely proud to be part of this event and to share our insights and advice with our customers on the potential impacts of these new findings. We are committed to improving patient outcomes by enabling better testing and better treatment for precision medicine.

If you want to learn more about our services and solutions, contact us today here 

We hope you enjoyed our summary of ESMO 2023. Follow us on LinkedIn for more updates from Diaceutics.


  • LBA84 - Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): a randomised, phase 2 trial: ENZA-p (ANZUP 1901)
  • 1511O - Pembrolizumab plus Trastuzumab and Chemotherapy for HER2+ Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Survival results from the Phase 3, Randomized, Double-blind, Placebo-controlled KEYNOTE-811 Study
  • Session organised by Seagen: HER2-Targeted Therapies in mCRC: Are We Ready for a Paradigm Shift?
  • ๐˜“๐˜‰๐˜ˆ5 - ๐˜ˆ๐˜ฎ๐˜ช๐˜ท๐˜ข๐˜ฏ๐˜ต๐˜ข๐˜ฎ๐˜ข๐˜ฃ ๐˜—๐˜ญ๐˜ถ๐˜ด ๐˜Š๐˜ฉ๐˜ฆ๐˜ฎ๐˜ฐ๐˜ต๐˜ฉ๐˜ฆ๐˜ณ๐˜ข๐˜ฑ๐˜บ ๐˜ท๐˜ด ๐˜Š๐˜ฉ๐˜ฆ๐˜ฎ๐˜ฐ๐˜ต๐˜ฉ๐˜ฆ๐˜ณ๐˜ข๐˜ฑ๐˜บ ๐˜ข๐˜ด ๐˜๐˜ช๐˜ณ๐˜ด๐˜ต-๐˜ญ๐˜ช๐˜ฏ๐˜ฆ ๐˜›๐˜ณ๐˜ฆ๐˜ข๐˜ต๐˜ฎ๐˜ฆ๐˜ฏ๐˜ต ๐˜ช๐˜ฏ ๐˜Œ๐˜Ž๐˜๐˜™ ๐˜Œ๐˜น๐˜ฐ๐˜ฏ 20 ๐˜๐˜ฏ๐˜ด๐˜ฆ๐˜ณ๐˜ต๐˜ช๐˜ฐ๐˜ฏ-๐˜ฎ๐˜ถ๐˜ต๐˜ข๐˜ต๐˜ฆ๐˜ฅ ๐˜ˆ๐˜ฅ๐˜ท๐˜ข๐˜ฏ๐˜ค๐˜ฆ๐˜ฅ ๐˜•๐˜ฐ๐˜ฏ-๐˜ด๐˜ฎ๐˜ข๐˜ญ๐˜ญ ๐˜Š๐˜ฆ๐˜ญ๐˜ญ ๐˜“๐˜ถ๐˜ฏ๐˜จ ๐˜Š๐˜ข๐˜ฏ๐˜ค๐˜ฆ๐˜ณ (๐˜•๐˜š๐˜Š๐˜“๐˜Š): ๐˜—๐˜ณ๐˜ช๐˜ฎ๐˜ข๐˜ณ๐˜บ ๐˜™๐˜ฆ๐˜ด๐˜ถ๐˜ญ๐˜ต๐˜ด ๐˜๐˜ณ๐˜ฐ๐˜ฎ ๐˜—๐˜ˆ๐˜—๐˜๐˜“๐˜“๐˜–๐˜•, ๐˜ข ๐˜™๐˜ข๐˜ฏ๐˜ฅ๐˜ฐ๐˜ฎ๐˜ช๐˜ป๐˜ฆ๐˜ฅ ๐˜—๐˜ฉ๐˜ข๐˜ด๐˜ฆ 3 ๐˜Ž๐˜ญ๐˜ฐ๐˜ฃ๐˜ข๐˜ญ ๐˜š๐˜ต๐˜ถ๐˜ฅ๐˜บ
  • ๐˜“๐˜‰๐˜ˆ4 - ๐˜™๐˜ข๐˜ฏ๐˜ฅ๐˜ฐ๐˜ฎ๐˜ช๐˜ป๐˜ฆ๐˜ฅ ๐˜—๐˜ฉ๐˜ข๐˜ด๐˜ฆ 3 ๐˜š๐˜ต๐˜ถ๐˜ฅ๐˜บ ๐˜ฐ๐˜ง ๐˜๐˜ช๐˜ณ๐˜ด๐˜ต-๐˜ญ๐˜ช๐˜ฏ๐˜ฆ ๐˜š๐˜ฆ๐˜ญ๐˜ฑ๐˜ฆ๐˜ณ๐˜ค๐˜ข๐˜ต๐˜ช๐˜ฏ๐˜ช๐˜ฃ ๐˜ท๐˜ฆ๐˜ณ๐˜ด๐˜ถ๐˜ด ๐˜Š๐˜ฉ๐˜ฆ๐˜ฎ๐˜ฐ๐˜ต๐˜ฉ๐˜ฆ๐˜ณ๐˜ข๐˜ฑ๐˜บ ๐˜ข๐˜ฏ๐˜ฅ ๐˜—๐˜ฆ๐˜ฎ๐˜ฃ๐˜ณ๐˜ฐ๐˜ญ๐˜ช๐˜ป๐˜ถ๐˜ฎ๐˜ข๐˜ฃ ๐˜ช๐˜ฏ ๐˜™๐˜Œ๐˜› ๐˜๐˜ถ๐˜ด๐˜ช๐˜ฐ๐˜ฏ-๐˜ฑ๐˜ฐ๐˜ด๐˜ช๐˜ต๐˜ช๐˜ท๐˜ฆ ๐˜•๐˜š๐˜Š๐˜“๐˜Š
  • ๐˜“๐˜‰๐˜ˆ2 - ๐˜ˆ๐˜“๐˜๐˜•๐˜ˆ: ๐˜ฆ๐˜ง๐˜ง๐˜ช๐˜ค๐˜ข๐˜ค๐˜บ ๐˜ข๐˜ฏ๐˜ฅ ๐˜ด๐˜ข๐˜ง๐˜ฆ๐˜ต๐˜บ ๐˜ฐ๐˜ง ๐˜ข๐˜ฅ๐˜ซ๐˜ถ๐˜ท๐˜ข๐˜ฏ๐˜ต ๐˜ข๐˜ญ๐˜ฆ๐˜ค๐˜ต๐˜ช๐˜ฏ๐˜ช๐˜ฃ ๐˜ท๐˜ฆ๐˜ณ๐˜ด๐˜ถ๐˜ด ๐˜ค๐˜ฉ๐˜ฆ๐˜ฎ๐˜ฐ๐˜ต๐˜ฉ๐˜ฆ๐˜ณ๐˜ข๐˜ฑ๐˜บ ๐˜ช๐˜ฏ ๐˜ฑ๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต๐˜ด ๐˜ธ๐˜ช๐˜ต๐˜ฉ ๐˜ฆ๐˜ข๐˜ณ๐˜ญ๐˜บ-๐˜ด๐˜ต๐˜ข๐˜จ๐˜ฆ ๐˜ˆ๐˜“๐˜’+ ๐˜ฏ๐˜ฐ๐˜ฏ-๐˜ด๐˜ฎ๐˜ข๐˜ญ๐˜ญ ๐˜ค๐˜ฆ๐˜ญ๐˜ญ ๐˜ญ๐˜ถ๐˜ฏ๐˜จ ๐˜ค๐˜ข๐˜ฏ๐˜ค๐˜ฆ๐˜ณ (๐˜•๐˜š๐˜Š๐˜“๐˜Š)
  • 1315๐˜”๐˜– - ๐˜‹๐˜ถ๐˜ณ๐˜ข๐˜ฃ๐˜ญ๐˜ฆ ๐˜ฆ๐˜ง๐˜ง๐˜ช๐˜ค๐˜ข๐˜ค๐˜บ ๐˜ฐ๐˜ง ๐˜ป๐˜ฆ๐˜ฏ๐˜ฐ๐˜ค๐˜ถ๐˜ต๐˜ถ๐˜ป๐˜ถ๐˜ฎ๐˜ข๐˜ฃ, ๐˜ข ๐˜๐˜Œ๐˜™2 ๐˜น ๐˜๐˜Œ๐˜™3 ๐˜ฃ๐˜ช๐˜ด๐˜ฑ๐˜ฆ๐˜ค๐˜ช๐˜ง๐˜ช๐˜ค ๐˜ข๐˜ฏ๐˜ต๐˜ช๐˜ฃ๐˜ฐ๐˜ฅ๐˜บ, ๐˜ช๐˜ฏ ๐˜ข๐˜ฅ๐˜ท๐˜ข๐˜ฏ๐˜ค๐˜ฆ๐˜ฅ ๐˜•๐˜™๐˜Ž1 ๐˜ง๐˜ถ๐˜ด๐˜ช๐˜ฐ๐˜ฏ-๐˜ฑ๐˜ฐ๐˜ด๐˜ช๐˜ต๐˜ช๐˜ท๐˜ฆ (๐˜•๐˜™๐˜Ž1+) ๐˜ฏ๐˜ฐ๐˜ฏ-๐˜ด๐˜ฎ๐˜ข๐˜ญ๐˜ญ ๐˜ค๐˜ฆ๐˜ญ๐˜ญ ๐˜ญ๐˜ถ๐˜ฏ๐˜จ ๐˜ค๐˜ข๐˜ฏ๐˜ค๐˜ฆ๐˜ณ (๐˜•๐˜š๐˜Š๐˜“๐˜Š)
  • ๐˜“๐˜‰๐˜ˆ6 - ๐˜Œ๐˜-302/๐˜’๐˜Œ๐˜ ๐˜•๐˜–๐˜›๐˜Œ-๐˜ˆ39: ๐˜–๐˜ฑ๐˜ฆ๐˜ฏ-๐˜“๐˜ข๐˜ฃ๐˜ฆ๐˜ญ, ๐˜™๐˜ข๐˜ฏ๐˜ฅ๐˜ฐ๐˜ฎ๐˜ช๐˜ป๐˜ฆ๐˜ฅ ๐˜—๐˜ฉ๐˜ข๐˜ด๐˜ฆ 3 ๐˜š๐˜ต๐˜ถ๐˜ฅ๐˜บ ๐˜ฐ๐˜ง ๐˜Œ๐˜ฏ๐˜ง๐˜ฐ๐˜ณ๐˜ต๐˜ถ๐˜ฎ๐˜ข๐˜ฃ ๐˜๐˜ฆ๐˜ฅ๐˜ฐ๐˜ต๐˜ช๐˜ฏ ๐˜ช๐˜ฏ ๐˜Š๐˜ฐ๐˜ฎ๐˜ฃ๐˜ช๐˜ฏ๐˜ข๐˜ต๐˜ช๐˜ฐ๐˜ฏ ๐˜ธ๐˜ช๐˜ต๐˜ฉ ๐˜—๐˜ฆ๐˜ฎ๐˜ฃ๐˜ณ๐˜ฐ๐˜ญ๐˜ช๐˜ป๐˜ถ๐˜ฎ๐˜ข๐˜ฃ (๐˜Œ๐˜+๐˜—) ๐˜๐˜ด ๐˜Š๐˜ฉ๐˜ฆ๐˜ฎ๐˜ฐ๐˜ต๐˜ฉ๐˜ฆ๐˜ณ๐˜ข๐˜ฑ๐˜บ (๐˜Š๐˜ฉ๐˜ฆ๐˜ฎ๐˜ฐ) ๐˜ช๐˜ฏ ๐˜—๐˜ณ๐˜ฆ๐˜ท๐˜ช๐˜ฐ๐˜ถ๐˜ด๐˜ญ๐˜บ ๐˜œ๐˜ฏ๐˜ต๐˜ณ๐˜ฆ๐˜ข๐˜ต๐˜ฆ๐˜ฅ ๐˜“๐˜ฐ๐˜ค๐˜ข๐˜ญ๐˜ญ๐˜บ ๐˜ˆ๐˜ฅ๐˜ท๐˜ข๐˜ฏ๐˜ค๐˜ฆ๐˜ฅ ๐˜”๐˜ฆ๐˜ต๐˜ข๐˜ด๐˜ต๐˜ข๐˜ต๐˜ช๐˜ค ๐˜œ๐˜ณ๐˜ฐ๐˜ต๐˜ฉ๐˜ฆ๐˜ญ๐˜ช๐˜ข๐˜ญ ๐˜Š๐˜ข๐˜ณ๐˜ค๐˜ช๐˜ฏ๐˜ฐ๐˜ฎ๐˜ข (๐˜ญ๐˜ข/๐˜ฎ๐˜œ๐˜Š)
  • ๐˜“๐˜‰๐˜ˆ7 - ๐˜•๐˜ช๐˜ท๐˜ฐ๐˜ญ๐˜ถ๐˜ฎ๐˜ข๐˜ฃ ๐˜ฑ๐˜ญ๐˜ถ๐˜ด ๐˜จ๐˜ฆ๐˜ฎ๐˜ค๐˜ช๐˜ต๐˜ข๐˜ฃ๐˜ช๐˜ฏ๐˜ฆ-๐˜ค๐˜ช๐˜ด๐˜ฑ๐˜ญ๐˜ข๐˜ต๐˜ช๐˜ฏ ๐˜ท๐˜ฆ๐˜ณ๐˜ด๐˜ถ๐˜ด ๐˜จ๐˜ฆ๐˜ฎ๐˜ค๐˜ช๐˜ต๐˜ข๐˜ฃ๐˜ช๐˜ฏ๐˜ฆ-๐˜ค๐˜ช๐˜ด๐˜ฑ๐˜ญ๐˜ข๐˜ต๐˜ช๐˜ฏ ๐˜ข๐˜ญ๐˜ฐ๐˜ฏ๐˜ฆ ๐˜ง๐˜ฐ๐˜ณ ๐˜ฑ๐˜ณ๐˜ฆ๐˜ท๐˜ช๐˜ฐ๐˜ถ๐˜ด๐˜ญ๐˜บ ๐˜ถ๐˜ฏ๐˜ต๐˜ณ๐˜ฆ๐˜ข๐˜ต๐˜ฆ๐˜ฅ ๐˜ถ๐˜ฏ๐˜ณ๐˜ฆ๐˜ด๐˜ฆ๐˜ค๐˜ต๐˜ข๐˜ฃ๐˜ญ๐˜ฆ ๐˜ฐ๐˜ณ ๐˜ฎ๐˜ฆ๐˜ต๐˜ข๐˜ด๐˜ต๐˜ข๐˜ต๐˜ช๐˜ค ๐˜ถ๐˜ณ๐˜ฐ๐˜ต๐˜ฉ๐˜ฆ๐˜ญ๐˜ช๐˜ข๐˜ญ ๐˜ค๐˜ข๐˜ณ๐˜ค๐˜ช๐˜ฏ๐˜ฐ๐˜ฎ๐˜ข: ๐˜ณ๐˜ฆ๐˜ด๐˜ถ๐˜ญ๐˜ต๐˜ด ๐˜ง๐˜ณ๐˜ฐ๐˜ฎ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ฑ๐˜ฉ๐˜ข๐˜ด๐˜ฆ 3 ๐˜Š๐˜ฉ๐˜ฆ๐˜ค๐˜ฌ๐˜”๐˜ข๐˜ต๐˜ฆ 901 ๐˜ต๐˜ณ๐˜ช๐˜ข๐˜ญ
  • 652๐˜– - ๐˜—๐˜ณ๐˜ฆ๐˜ญ๐˜ช๐˜ฎ๐˜ช๐˜ฏ๐˜ข๐˜ณ๐˜บ ๐˜ค๐˜ญ๐˜ช๐˜ฏ๐˜ช๐˜ค๐˜ข๐˜ญ ๐˜ข๐˜ค๐˜ต๐˜ช๐˜ท๐˜ช๐˜ต๐˜บ ๐˜ฐ๐˜ง ๐˜™๐˜”๐˜Š-6236, ๐˜ข ๐˜ง๐˜ช๐˜ณ๐˜ด๐˜ต-๐˜ช๐˜ฏ-๐˜ค๐˜ญ๐˜ข๐˜ด๐˜ด, ๐˜™๐˜ˆ๐˜š-๐˜ด๐˜ฆ๐˜ญ๐˜ฆ๐˜ค๐˜ต๐˜ช๐˜ท๐˜ฆ, ๐˜ต๐˜ณ๐˜ช-๐˜ค๐˜ฐ๐˜ฎ๐˜ฑ๐˜ญ๐˜ฆ๐˜น ๐˜™๐˜ˆ๐˜š-๐˜”๐˜œ๐˜“๐˜›๐˜(๐˜–๐˜•) ๐˜ช๐˜ฏ๐˜ฉ๐˜ช๐˜ฃ๐˜ช๐˜ต๐˜ฐ๐˜ณ ๐˜ช๐˜ฏ ๐˜ฑ๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต๐˜ด ๐˜ธ๐˜ช๐˜ต๐˜ฉ ๐˜’๐˜™๐˜ˆ๐˜š ๐˜ฎ๐˜ถ๐˜ต๐˜ข๐˜ฏ๐˜ต ๐˜ฑ๐˜ข๐˜ฏ๐˜ค๐˜ณ๐˜ฆ๐˜ข๐˜ต๐˜ช๐˜ค ๐˜ฅ๐˜ถ๐˜ค๐˜ต๐˜ข๐˜ญ ๐˜ข๐˜ฅ๐˜ฆ๐˜ฏ๐˜ฐ๐˜ค๐˜ข๐˜ณ๐˜ค๐˜ช๐˜ฏ๐˜ฐ๐˜ฎ๐˜ข (๐˜—๐˜‹๐˜ˆ๐˜Š) ๐˜ข๐˜ฏ๐˜ฅ ๐˜ฏ๐˜ฐ๐˜ฏ-๐˜ด๐˜ฎ๐˜ข๐˜ญ๐˜ญ ๐˜ค๐˜ฆ๐˜ญ๐˜ญ ๐˜ญ๐˜ถ๐˜ฏ๐˜จ ๐˜ค๐˜ข๐˜ฏ๐˜ค๐˜ฆ๐˜ณ (๐˜•๐˜š๐˜Š๐˜“๐˜Š)
  • How to implement local LoE1A HRD testing: experience of a center of excellence - Carsten Denkert (Marburg, Germany)
  • LBA14 - Amivantamab Plus Lazertinib vsOsimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced
    Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3,
    Global, Randomized, Controlled Trial
  • LBA15 - Amivantamab Plus Chemotherapy(With or Without Lazertinib) vs Chemotherapy in EGFR-mutated Advanced NSCLC
    After Progression on Osimertinib: MARIPOSA-2, a Phase 3, Global, Randomized,
    Controlled Trial
  • Artificial intelligence in prognostication - chaired by Sanjay Aneja (New Heaven, United States of America) and Anne Vincent-Salomon (Paris, France)

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny